Back to search
FDAFDA · Food and drugs·Recall number D-0775-2021

Cyclobenzaprine Hydrochloride Tablets, 7.5mg, 100 count tablets per bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc. Fort Lauderdale, FL 33314, NDC 70199-014-01

Published September 8, 2021 · Recall initiated: July 29, 2021

Summary

FDA records drug Class II recall D-0775-2021, published September 8, 2021 and initiated July 29, 2021. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 4,587 bottles; Lot: 1408822A, exp. date 08/2023 (labeler - Casper). Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Product was distributed nationwide.
Lot
1408822A, exp. date 08/2023 (labeler - Casper)
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cyclobenzaprine Hydrochloride Tablets, 7.5mg, 100 count tablets per bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc. Fort Lauderdale, FL 33314, NDC 70199-014-01 recalled?

Yes. FDA published recall D-0775-2021 on September 8, 2021. Reported hazard: CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

What should I do if I have this product?

Voluntary: Firm initiated · Letter